CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --

马萨诸塞州剑桥，2026年8月6日（环球社电）--

Biogen

渤健

Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.

Inc.（纳斯达克股票代码：BIIB）今日宣布完成对RayThera Inc.的收购。RayThera是一家私人持有的生物技术公司，专注于发现和开发免疫学领域的小分子疗法。

The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026.

此次收购巩固了渤健不断增长的免疫学产品组合，增加了多种具有治疗多种适应症免疫介导疾病潜力的资产。其领先项目已于2026年7月进入第一阶段开发。

“We are excited about the potential of these immunology assets as we continue to strengthen and diversify our pipeline for long-term growth,” said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. “With the lead program now in Phase 1, this acquisition highlights strong execution on our open innovation model in sourcing external opportunities and reflects our continued investment in immunology as a strategic growth area.”.

“随着我们不断加强和多元化产品管线以实现长期增长，我们对这些免疫学资产的潜力感到兴奋。”渤健（Biogen）执行副总裁兼开发主管Priya Singhal医学博士、公共卫生硕士表示。“随着领先项目现已进入一期临床阶段，此次收购凸显了我们在获取外部机会方面对开放创新模式的高效执行，也反映了我们将免疫学作为战略增长领域持续投入的决心。”

About Biogen

关于渤健

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.

百健成立于1978年，是一家领先的生物技术公司，通过开拓创新科学，提供新药以改变患者生活，并为股东和社区创造价值。我们运用对人类生物学的深刻理解，利用不同技术平台推进首创疗法或治疗手段，以实现更优的治疗效果。

Our approach is to take bold risks, balanced with return on investment to deliver long-term growth..

我们的方法是在大胆冒险与投资回报之间取得平衡，以实现长期增长。

We routinely post information that may be important to investors on our website at

我们会在我们的网站上定期发布可能对投资者重要的信息，网址为

www.biogen.com

www.biogen.com

. Follow us on social media -

在社交媒体上关注我们 -

Facebook

脸书

,

，

LinkedIn

领英

,

，

X

X

,

，

YouTube

YouTube

.

。

Biogen Safe Harbor

渤健安全港声明

This press release contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the “Safe Harbor” provisions of the PSLRA. This press release contains forward-looking statements, including relating to: the anticipated benefits of the RayThera Inc.

本新闻稿包含根据1995年《私人证券诉讼改革法案》（PSLRA）的规定作出的前瞻性陈述，旨在获得该法案“安全港”条款的保护。本新闻稿包含前瞻性陈述，包括涉及以下内容：RayThera Inc.的预期收益。

acquisition (the “Acquisition”); our growing immunology portfolio, including the potential strengthening and diversification of our pipeline for long-term growth; our investment in immunology as a strategic growth area; and the anticipated financial impacts of the Acquisition. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning.

收购（“本次收购”）；我们不断增长的免疫学产品组合，包括为长期增长而潜在加强和多样化我们的研发管线；我们将免疫学作为战略增长领域的投资；以及本次收购预期的财务影响。这些前瞻性陈述可能伴随使用如下词语：“旨在”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“预测”、“目标”、“指引”、“希望”、“打算”、“可以”、“目的”、“展望”、“计划”、“有可能”、“潜在”、“预言”、“规划”、“前景”、“应当”、“指标”、“将”、“会”，以及其他具有类似含义的词语和术语。

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

药物研发和商业化涉及高度风险，仅有少数研发项目最终实现产品的商业化。早期临床试验的结果可能无法反映完整结果或后期及更大规模临床试验的结果，也不能确保获得监管批准。

You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements..

您不应过度依赖这些陈述。鉴于其前瞻性性质，这些陈述涉及重大风险和不确定性，可能基于不准确的假设，并可能导致实际结果与这些陈述所反映的结果存在重大差异。

These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: the possibility that the thresholds for clinical and regulatory milestone payments are never met; results of litigation, settlements and investigations; actions by third parties, including governmental agencies; unexpected costs, charges or expenses resulting from the Acquisition; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Acquisition; the risk that Biogen may not be able to successfully integrate the business of RayThera and realize the expected benefits of the Acquisition in a timely manner or at all; uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products .

这些前瞻性陈述基于管理层当前的信念和假设以及管理层目前可获得的信息。鉴于其性质，我们无法保证这些前瞻性陈述中表达的任何结果会全部或部分实现。我们提醒，这些陈述受风险和不确定性的影响，其中许多超出我们的控制范围，并可能导致未来事件或结果与本文件中陈述或暗示的内容存在重大差异，包括但不限于以下因素：临床和监管里程碑付款的阈值可能永远无法达到；诉讼、和解和调查的结果；包括政府机构在内的第三方采取的行动；因收购而产生的意外成本、费用或支出；因宣布或完成收购而导致的潜在不利反应或业务关系变化；Biogen 可能无法成功整合 RayThera 的业务，或无法及时或根本无法实现收购的预期效益的风险；我们在开发、许可或获取其他候选产品或现有产品的额外适应症方面的长期成功的不确定性；与产品批准、现有产品额外适应症的批准、销售、定价、增长、报销以及已上市和管线产品的推出相关的行动的预期、计划、前景和时间安排；生物制药和医疗保健行业以及我们参与竞争的任何其他市场中产品竞争加剧的潜在影响，包括来自新原研疗法、仿制药、前药和现有产品的生物类似药的竞争加剧。

www.sec.gov

www.sec.gov

.

。

These statements speak only as of date hereof and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated, or projected.

上述声明仅反映截至本文件发布之日的情况，并基于我们目前可获得的信息和估计。如果已知或未知的风险或不确定性成为现实，或者基本假设被证明不准确，实际结果可能与过去的结果以及预期、估计或预测的结果存在重大差异。

Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A.

提醒投资者不要过度依赖前瞻性陈述。有关风险、不确定性及其他事项的进一步列表和描述，请参见我们截至2025年12月31日财政年度的10-K表格年度报告以及后续的10-Q表格报告，其中包括各报告中题为“关于前瞻性陈述的说明”和“第1A项”的部分。

Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise..

风险因素”，以及在我们随后提交的8-K表格报告中。除法律要求外，我们不承担任何义务公开更新任何前瞻性陈述，无论是由于新信息、未来事件、情况变化还是其他原因。

Biogen Digital Media Disclosure

渤健数字媒体披露

From time to time, we have used, or expect in the future to use, our investor relations website (

我们不时使用或预计未来将使用我们的投资者关系网站（

investors.biogen.com

investors.biogen.com

), the Biogen LinkedIn account (

），渤健的领英账号（

linkedin.com/company/biogen-

linkedin.com/company/biogen-

) and the Biogen X account (

）以及 Biogen X 账户（

https://x.com/biogen

https://x.com/biogen

) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors..

）作为以广泛、非排他性的方式向公众披露信息的手段，包括用于满足美国证券交易委员会（SEC）《公平披露条例》（Reg FD）的目的。因此，投资者除了关注我们的新闻稿、SEC备案文件、公开电话会议和网站外，还应监控我们的投资者关系网站及这些社交媒体渠道，因为发布在这些平台上的信息可能对投资者具有重大影响。

MEDIA CONTACT:

媒体联系人：

Madeleine Shin

马德琳·辛

+ 1 781 464 3260

+1 781 464 3260

public.affairs@biogen.com

public.affairs@biogen.com

INVESTOR CONTACT:

投资者联系：

Tim Power

蒂姆·鲍尔

+1 781 464 2442

+1 781 464 2442

IR@biogen.com

IR@biogen.com